EIF4A1 and neoplasm: As eIF4A showed a dramatic increase following longitudinal paclitaxel exposure, we pharmacologically targeted eIF4A with RocA in therapy-naïve and Pac 200 SUM-159PT tumor cells under both adherent and non-adherent (low attachment poly-HEMA coated) conditions.